Clinical Immunology Unit, Department of Internal Medicine (DIMI), University of Genoa and Ospedale Policlinico San Martino, Viale Benedetto XV, n. 6, 16132, Genoa, Italy.
Anatomic Pathology Unit, Department of Surgical and Diagnostic Sciences, University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy.
Virchows Arch. 2018 Oct;473(4):425-433. doi: 10.1007/s00428-018-2379-0. Epub 2018 May 29.
To analyze expression of human leukocyte antigen-G (HLA-G) in gastric adenocarcinoma and correlate its expression with histological and clinical variables. A continuous series of 94 unselected patients with gastric adenocarcinoma (stage I to III) were selected. All histological and clinical variables were collected including the intensity of intra- and peri-tumor lymphocytic infiltration. HLA-G expression was investigated using immunohistochemistry. All histological samples analyzed for HLA-G expression were taken from the primary gastric lesion and included non-neoplastic mucosa. Evaluation of HLA-G expression was performed on the transition zone between tumor and non-neoplastic mucosa, and the invasive front of the tumor and assessment was performed as follows: percentage of positive (strong expression vs weak) cells. A variable amount of HLA-G-positive tumor cells was found in 24 out of 94 cases (25.5%). No significant correlation was found between HLA-G expression and other clinicopathological variables (sex, age, stage, grade, histotype). The overall median survival was worse in patients with HLA-G-positive adenocarcinoma (24.3 months, CI 7.7-41.0) compared to those with HLA-G-negative tumors (66.3 months, CI 53.0-79.7; p < 0.0001). Two- and 5-year survival rates of HLA-G-negative patients were 88 and 44%, respectively, while were 42 and 11% in those HLA-G-positive. This trend was observed in all stages but was more marked in stage III. HLA-G expression is associated with poor survival in stage III gastric cancer patients and represents a possible immunoescape mechanism of cancer cells.
分析人白细胞抗原-G(HLA-G)在胃腺癌中的表达,并将其表达与组织学和临床变量相关联。选择了 94 例未经选择的胃腺癌(I 期至 III 期)连续患者。收集了所有组织学和临床变量,包括肿瘤内和周围淋巴细胞浸润的强度。使用免疫组织化学法检测 HLA-G 表达。对所有分析 HLA-G 表达的组织学样本均取自原发性胃病变,并包括非肿瘤性黏膜。HLA-G 表达的评估是在肿瘤和非肿瘤性黏膜之间的过渡区进行的,评估方法如下:阳性(强表达与弱表达)细胞的百分比。在 94 例病例中的 24 例(25.5%)中发现了数量不定的 HLA-G 阳性肿瘤细胞。HLA-G 表达与其他临床病理变量(性别、年龄、分期、分级、组织类型)之间未发现显著相关性。HLA-G 阳性腺癌患者的总体中位生存期更差(24.3 个月,CI 7.7-41.0),而 HLA-G 阴性肿瘤患者的中位生存期为 66.3 个月(CI 53.0-79.7;p<0.0001)。HLA-G 阴性患者的 2 年和 5 年生存率分别为 88%和 44%,而 HLA-G 阳性患者分别为 42%和 11%。这种趋势在所有分期中都观察到,但在 III 期更为明显。HLA-G 表达与 III 期胃癌患者的不良预后相关,代表癌细胞可能的免疫逃逸机制。